Financial Summary

Consolidated Income Statement

	2008 £000's	2007 £000's	2006 £000's	2005 £000's
Revenue	1,855	13	1,135	-
Operating expenses
Research and development	(11,225)	(31,136)	(18,329)	(15,752)
Impairment of acquired Intellectual Property Rights	-	-	-	(1,300)
Total research and development expenses	(11,225)	(31,136)	(18,329)	(17,052)
Management and administration	(1,773)	(1,713)	(1,493)	(1,366)
Share-based payment	(602)	(676)	(989)	(486)
Total management and administration expenses	(2,375)	(2,389)	(2,482)	(1,852)
Total operating expenses	(13,600)	(33,525)	(20,811)	(18,904)
Operating Loss	(11,745)	(33,512)	(19,676)	(18,904)
Investment Income	252	845	1,045	1,228
(Loss)/gain on foreign exchange transactions	-	(36)	(338)	76
Loss on ordinary activities before taxation	(11,493)	(32,703)	(18,969)	(17,600)
Taxation on loss on ordinary activities	1,433	1,458	1,005	892
Loss for the financial year being the retained loss for the year attributed to the members of Alizyme plc	(10,060)	(31,245)	(17,964)	(16,708)
Loss per share for the year - basic and diluted	(4.6)p	(15.6)p	(9.9)p	(10.1)p

The financial information above is derived from the Annual Report and Accounts of Alizyme plc, but does not comprise the Company's statutory accounts within the meaning of section 240(5) of the Companies Act 1985

Consolidated Balance Sheet

	2008 £000's	2007 £000's	2006 £000's	2005 £000's
Non-current assets
Property, plant and equipment	90	176	65	41
Current assets
Trade and other receivables	3,024	4,611	5,305	6,328
Money market investments	-	3,800	5,300	9,750
Cash and cash equivalents	2,185	2,002	22,448	21,062
	5,209	10,413	33,053	37,140
Current liabilities
Trade and other payables	(2,337)	(8,888)	(2,600)	(5,048)
Deferred revenue	(187)	(80)	-	-
Bank overdrafts	-	-	-	(43)
	(2,524)	(8,968)	(2,600)	(5,091)
Net current assets	2,685	1,445	30,453	32,049
Total assets less current liabilities	2,775	1,621	30,518	32,090
Non-current liabilities
Deferred revenue	(2,447)	(1,115)	-	-
Long-term provisions	-	(8)	(84)	(237)
	(2,447)	(1,123)	(84)	(237)
Net assets	328	498	30,434	31,853
Equity shareholders' funds
Share capital	4,422	4,021	3,994	3,575
Share premium account	116,599	107,712	107,106	91,969
Capital reserve	1,530	1,530	1,530	1,530
Share-based payment reserve	3,144	2,542	1,866	877
Retained loss	(125,367)	(115,307)	(84,062)	(66,098)
Total equity	328	498	30,434	31,853